持续更新中,敬请关注!
Continuous updates are in progress, please stay tuned!
(66) | |
(65)EVERCORE ISI Equity Research – Biotech, Pharma, Spec Pharma:ESMO DEEP DIVE (including World Lung – WCLC) | |
(64)China Strategy | If not now, when? 10 reasons to buy China equit(Goldman Sachs,October 7,2024) | |
(63)STAT News: 12 people changing the course of the Chinese biopharma industry | |
(62)CAR T-cell therapy in autoimmune diseases(thelancet, September 22,2023) | |
(61)Roche Pharma Day – 2024 | |
(60)Roche Pharma Day – 2023 | |
(59)Roche Pharma Day – 2022 | |
(58)2021 Roche Pharma Day Infectious Diseases | |
(57)2024 Summer Series of R&D Webinars Part IV – Obesity Programs(Arrowhead, August 14, 2024) | |
(56)中康有数 | 药品院外零售市场分析(药店 vs O2O vs B2C)(2024年9月) | |
(55)全球医药、医疗行业 – 代谢疾病新药研发系列(三):肝胆代谢疾病及以肝脏递送为靶向的核酸类药物的崛起 | |
(54)Moderna Investor Day R&D and Business Updates (September 12, 2024) | |
(53)Moderna:Vaccine & Business Updates (March 27,2024) | |
(52)Drug Development Failure: How GLP-1 Development Was Abandoned in 1990 | |
(51)外商投资准入特别管理措施(负面清单)(2024 年版) | |
(50)外商投资准入特别管理措施(负面清单)(2021 年版) | |
(49)阅读美国制药的20点体会最新版 | |
(48)中国药企海外授权进展 | |
(47)细胞治疗行业深度报告:实体瘤和异体CAR-T破局在即,看好本土突围 | |
(46)CAR-T细胞疗法行业图谱 | |
(45)卓越的全球化端到端创新药CDMO服务平台业务介绍 | |
(44)诱导多能干细胞iPSC产业现状 | |
(43)新药临床试验简介 | |
(42)新药加快上市程序概述 | |
(41)思维导图版2023年10月全国各地肿瘤临床试验项目汇总 | |
(40)生物学概念与途径 | |
(39)全球已上市偶联抗体技术审评汇编 | |
(38)全球创新药研发格局监测-神经精神领域篇 | |
(37)狂热的追求 | |
(36)大型制药企业原始创新来源 | |
(35)TERM SHEET EXAMPLE | |
(34)Press Release: Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences |
|
(33)Pfizer Pipeline_Update_31JAN2023 | |
(32)Exploration of the antibody drug conjugate clinical landscape | |
(31)2022 Novel Small Molecule Drug Approvals | |
(30)Biopharma dealmaking: negotiating your term sheet | |
(29)Q2_2024_Biopharma_Report_Preview | |
(28)信达生物制药_2024中期业绩报告演示文稿 | |
(27)AACR2024_Regular_Abstracts | |
(26)【CDE】2023年度药品审评报告 | |
(25)Biopharma Private Placement Insights – 1H 2024 | |
(24)2023医保目录专题报告 | |
(23)BIOHAVEN R&D Day 2024 | |
(22)2023年AI制药行业报告 | |
(21)2023年中国生物医药投融资蓝皮书 | |
(20)2024 ASCO Abstract | |
(19)Foreign investment in Chinas biotechs continues big drop | |
(18)Strengthening Pathways for Cell and Gene Therapies-Current State and Future Scenarios | |
(17)Q2 2024 U.S. Biopharma Licensing and Venture Report | |
(16)2024中国罕见病行业趋势观察报告 | |
(15)Alzheimer’s disease drug development pipeline: 2024 | |
(14)Navigating global market: A-deep-dive-into-the-Chinese-pharmaceutical-industry-global-expansion_compressed | |
(13)Artificial Intelligence in Drug Design (Alexander Heifetz) (Z-Library) | |
(12)FDA / CDER: novel drug approvals 2023 (n=55); FDA / CBER: new BLA/therapeutics approvals 2023 (n=17); Biopharma M&A 2023 (37 deals; total value: c.$142bn; Notable biotech IPOs 2023 | |
(11)Immune System Disorder and Cancer-Associated Cachexia | |
(10)Cell Death | |
(9)GLP1-Winners-and-Losers | |
(8)Global report on hypertension | |
(7)Obesity drugs aren’t always forever. What happens when you quit | |
(6)阿尔茨海默病居家筛查专家共识-2024 | |
(5)医美行业2023年度报告 | |
(4)2023年度中国医院药品市场分析报告 | |
(3)中国阿尔茨海默病早期预防指南 2024 | |
(2)最值得关注的肿瘤药物预测——ASCO 2024 关键启示 | |
(1)特应性皮炎深度解析:药物开发、专利分析与风险评估 |
【免责声明】药时代官网分享的研究报告均为方便读者朋友们个人学习之目的,非商业盈利目的。我们尽力获得报告作者的同意。如果您对这里分享的报告有任何问题,敬请与我们联系,我们的邮箱是:contact@drugtimes.cn。衷心感谢您的关注、理解和支持!
【Disclaimer】The research reports shared on the DrugTimes official website are for the personal learning purposes of our readers and not for commercial profit. We make every effort to obtain the consent of the report authors. If you have any issues with the reports shared here, please contact us at our email: contact@drugtimes.cn. We sincerely appreciate your attention, understanding, and support!
发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权